MSON - Misonix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.91
-0.39 (-2.25%)
At close: 4:00PM EST

16.91 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close17.30
Open17.40
Bid16.70 x 800
Ask21.50 x 1800
Day's Range16.58 - 17.40
52 Week Range14.13 - 27.54
Volume98,258
Avg. Volume42,875
Market Cap255.103M
Beta (3Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-0.32
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.33
  • Thomson Reuters StreetEvents

    Edited Transcript of MSON earnings conference call or presentation 7-Nov-19 9:30pm GMT

    Q1 2020 Misonix Opco Inc Earnings Call

  • GlobeNewswire

    Misonix Fiscal 2020 First Quarter Record Quarterly Product Revenue Of $11.1 Million

    FARMINGDALE, N.Y., Nov. 07, 2019 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.

  • GlobeNewswire

    Misonix to Participate in Three Upcoming Investor Conferences

    FARMINGDALE, N.Y., Nov. 04, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and.

  • We're Not Very Worried About Misonix's (NASDAQ:MSON) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Misonix's (NASDAQ:MSON) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • GlobeNewswire

    Misonix to Report Fiscal 2020 First Quarter Financial Results and Host Conference Call and Webcast on November 7

    FARMINGDALE, N.Y., Oct. 28, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire

    Misonix, Inc. Completes Acquisition of Regenerative Medical Company Solsys Medical

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it completed its previously announced acquisition of privately held Solsys Medical, LLC (“Solsys”), in an all-stock transaction valued at approximately $109 million on the date prior to closing. Solsys and its leading cellular and tissue-based wound treatment, TheraSkin, is highly complementary to Misonix’s cutting-edge ultrasonic wound debridement solution, SonicOne, providing Misonix with a large direct advanced wound care channel-to-market that will enable the Company to expand SonicOne sales, and together with TheraSkin, establish a new standard of care in the growing chronic wound care market.

  • How Much Of Misonix, Inc. (NASDAQ:MSON) Do Insiders Own?
    Simply Wall St.

    How Much Of Misonix, Inc. (NASDAQ:MSON) Do Insiders Own?

    Every investor in Misonix, Inc. (NASDAQ:MSON) should be aware of the most powerful shareholder groups. Institutions...

  • GuruFocus.com

    Misonix Inc (MSON) Files 10-K for the Fiscal Year Ended on June 30, 2019

    Misonix Inc (MSON) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. Misonix Inc designs, manufactures, markets and develops minimally invasive ultrasonic surgical device products. Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of MSON earnings conference call or presentation 14-Aug-19 8:30pm GMT

    Q4 2019 Misonix Inc Earnings Call

  • GlobeNewswire

    Misonix Reports Fourth Quarter and Fiscal Year 2019 Results

    FARMINGDALE, N.Y., Aug. 14, 2019 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • Benzinga

    Misonix's Earnings Preview

    Misonix (NASDAQ: MSON ) releases its next round of earnings this Wednesday, August 14. Here's Benzinga's essential guide to Misonix's Q2 earnings report. Earnings and Revenue Wall Street analysts see Misonix ...

  • Thomson Reuters StreetEvents

    Edited Transcript of MSON earnings conference call or presentation 8-May-19 8:30pm GMT

    Q3 2019 Misonix Inc Earnings Call

  • GlobeNewswire

    Misonix Announces CE Mark Approval for Nexus

    FARMINGDALE, N.Y., Aug. 12, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire

    Misonix to Report Fiscal 2019 Fourth Quarter Financial Results and Host Conference Call and Webcast on August 14

    FARMINGDALE, N.Y., Aug. 07, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire

    Misonix to Present at the 39th Annual Canaccord Genuity Growth Conference on August 8

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Canaccord Genuity 39th Annual Growth Conference held at the InterContinental Hotel in Boston, Massachusetts on Thursday, August 8, 2019. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation in the Vancouver Room at 11:00 a.m. ET that day. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • Benzinga

    The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arena Pharmaceuticals, ...

  • GlobeNewswire

    Misonix Announces Inclusion in the Russell 2000® and 3000 Indexes

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has been selected to be added to the broad-market Russell 2000 and 3000® Indexes as part of the annual reconstitution of the Russell stock indexes. The Russell index changes became effective at the market close on June 28, 2019.  Misonix is already included in the Russell MicroCap Index. “We are very pleased to be added to the Russell 2000 and 3000 Indexes,” stated Stavros Vizirgianakis, President and Chief Executive Officer of Misonix.

  • GlobeNewswire

    SEC Investigation of Misonix, Inc. Ends With No Action

    Misonix, Inc. (MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has received a letter from the Division of Enforcement of the Securities and Exchange Commission (the “SEC”) on June 18, 2019, stating that the SEC has concluded its investigation of Misonix and that, based on the information it has as of the date of the letter, it does not intend to recommend an enforcement action by the SEC against Misonix with respect to the matters described below. As previously disclosed, with the assistance of outside counsel, Misonix conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed Misonix’s products in China and Misonix’s knowledge of those business practices, which may have had implications under the U.S. Foreign Corrupt Practices Act, as well as into various internal controls issues identified during the investigation.

  • The Misonix (NASDAQ:MSON) Share Price Is Up 363% And Shareholders Are Delighted
    Simply Wall St.

    The Misonix (NASDAQ:MSON) Share Price Is Up 363% And Shareholders Are Delighted

    Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...

  • GlobeNewswire

    Misonix Receives U.S. FDA Clearance for Nexus, its Revolutionary Integrated Ultrasonic Surgical Platform

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for Nexus, its revolutionary ultrasonic surgical platform. Misonix will commence the commercialization of the Nexus platform in the United States in July. Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single fully integrated platform that will also serve to power future solutions.

  • GlobeNewswire

    Misonix to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor Conference held at the Depot Renaissance Minneapolis Hotel in Minneapolis, Minnesota on Wednesday, May 29, 2019. Misonix management will be available to meet with institutional investors in one-on-one meetings throughout the day at the conference. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • Associated Press

    Misonix: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Farmingdale, New York-based company said it had a loss of 17 cents. The maker of minimally invasive ultrasonic surgical devices for spine surgery posted revenue of $9.6 million ...

  • GlobeNewswire

    Misonix Reports Fiscal 2019 Third Quarter Revenue of $9.6 Million

    FARMINGDALE, N.Y., May 08, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • Benzinga

    Misonix Announces $97M Acquisition Of Solys Medical

    Medical device maker  Misonix, Inc. (NASDAQ: MSON ) announced Thursday that it entered a definitive agreement to acquire privately held  Solsys Medical, LLC  in an all-stock transaction valued at about $97 ...

  • GlobeNewswire

    Misonix, Inc. Enters Into Definitive Agreement to Acquire Regenerative Medical Company Solsys Medical for Approximately $97 Million

    FARMINGDALE, N.Y., May 02, 2019 (GLOBE NEWSWIRE) --  Misonix, Inc. (MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it has entered into a definitive agreement with Solsys Medical, LLC (“Solsys”), a privately held regenerative medical company, to acquire Solsys in an all-stock transaction valued at approximately $97 million. Under the terms of the agreement, Misonix will issue approximately 5.7 million new shares to Solsys unitholders.